Home > smh > Papers > 331
A multi-centre randomized, open-label phase II trial of erlotinib plus gemcitabine or gemcitabine monotherapy as first-line therapy in ECOG PS2 patients with chemo-naive advanced NSCLC
M. G. Michael, University of WollongongFollow Michael Johnston, Roche Prod Pty Ltd Stephen Clarke Richard De Boer, Royal Melbourne Hospital Phillip R. Clingan, University of WollongongFollow Nick Pavlakis, Royal N Shore Hosp
31631
DOWNLOADS
Since September 28, 2010
Life Sciences Commons, Physical Sciences and Mathematics Commons, Social and Behavioral Sciences Commons
Advanced Search